Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
96
imatinib treatment based on molecular alterations
According to biomarkers
According to biomarkers
Oslo University Hospital
Oslo, Norway
RECRUITINGRadiological response evaluation at 16 weeks of treatment
Standard radiological response evaluation, like RECIST criteria.
Time frame: 16 weeks
Molecular analyses predicting responses
Sequencing of tumor material and blood samples
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.